France Keeps Top Health Alert as Officials Brace for Another Heatwave 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
Spire Healthcare Shares Jump on £1.03 Billion Takeover Deal 
GLP-1 Weight-Loss Drug Use Surges Among U.S. Children 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Milei Threatens Falkland Oil Firms With Sanctions 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise 
Huawei Launches Mate XT2 Foldable Phone in China 
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback 
Add as a preferred source on Google
Chinese biotech company Bliss Biopharmaceutical (BlissBio) is reportedly considering a Hong Kong initial public offering (IPO) that could raise at least $150 million, according to Bloomberg sources. The Hangzhou-based cancer drug developer is working with financial advisers to evaluate the listing, although final decisions have yet to be made and the IPO size could still change. There is also a possibility the company may postpone or cancel the plan.
Founded in 2017, BlissBio focuses on antibody-drug conjugates (ADCs) that specifically target tumors. The company currently has multiple therapies in early-stage clinical trials, including Phase 1 and Phase 2 studies, as stated on its website. ADCs are a cutting-edge treatment combining antibodies with cancer-killing agents to selectively target cancer cells, offering potential breakthroughs in oncology.
Investor interest in China's biotech sector remains strong, especially for innovative oncology firms. A recent example is Duality Biotherapeutics Inc (HK:9606), which saw its shares nearly double after its Hong Kong IPO last month, reflecting growing confidence in homegrown pharmaceutical innovation.
If successful, BlissBio’s IPO would join a wave of Chinese biotech listings on the Hong Kong Stock Exchange, which has become a favored venue for healthcare companies seeking capital to fund clinical trials and expand their R&D pipelines. With increasing demand for novel cancer therapies in China and globally, the market is watching closely to see whether BlissBio moves forward with the offering.
